D
Lantern Pharma Inc.
LTRN
$3.93
$0.133.42%
D
Sell
2/26/2024Upgraded
Lantern Pharma Inc. (LTRN) was upgraded to D- from E+ on 2/26/2024 due to an increase in the volatility index, growth index and total return index. Earnings per share increased from -$0.4372 to -$0.2912, and EBIT increased 32.11% from -$5.19M to -$3.52M.
Lantern Pharma Inc. (LTRN) was upgraded to D- from E+ on 2/26/2024 due to an increase in the volatility index, growth index and total return index. Earnings per share increased from -$0.4372 to -$0.2912, and EBIT increased 32.11% from -$5.19M to -$3.52M.
E
Sell
10/23/2023Downgrade
Lantern Pharma Inc. (LTRN) was downgraded to E+ from D- on 10/23/2023 due to a decline in the volatility index and total return index.
Lantern Pharma Inc. (LTRN) was downgraded to E+ from D- on 10/23/2023 due to a decline in the volatility index and total return index.
D
Sell
10/6/2023Upgraded
Lantern Pharma Inc. (LTRN) was upgraded to D- from E+ on 10/6/2023 due to an increase in the volatility index.
Lantern Pharma Inc. (LTRN) was upgraded to D- from E+ on 10/6/2023 due to an increase in the volatility index.
E
Sell
9/21/2023Downgrade
Lantern Pharma Inc. (LTRN) was downgraded to E+ from D- on 9/21/2023 due to a decline in the volatility index and total return index.
Lantern Pharma Inc. (LTRN) was downgraded to E+ from D- on 9/21/2023 due to a decline in the volatility index and total return index.
D
Sell
8/31/2023Upgraded
Lantern Pharma Inc. (LTRN) was upgraded to D- from E+ on 8/31/2023 due to an increase in the volatility index.
Lantern Pharma Inc. (LTRN) was upgraded to D- from E+ on 8/31/2023 due to an increase in the volatility index.
E
Sell
8/16/2023Downgrade
Lantern Pharma Inc. (LTRN) was downgraded to E+ from D- on 8/16/2023 due to a decline in the volatility index and solvency index. The quick ratio declined from 18.45 to 15.9.
Lantern Pharma Inc. (LTRN) was downgraded to E+ from D- on 8/16/2023 due to a decline in the volatility index and solvency index. The quick ratio declined from 18.45 to 15.9.
D
Sell
8/3/2023Upgraded
Lantern Pharma Inc. (LTRN) was upgraded to D- from E+ on 8/3/2023 due to an increase in the volatility index and total return index.
Lantern Pharma Inc. (LTRN) was upgraded to D- from E+ on 8/3/2023 due to an increase in the volatility index and total return index.
E
Sell
7/19/2023Downgrade
Lantern Pharma Inc. (LTRN) was downgraded to E+ from D- on 7/19/2023 due to a decline in the volatility index.
Lantern Pharma Inc. (LTRN) was downgraded to E+ from D- on 7/19/2023 due to a decline in the volatility index.
D
Sell
6/28/2023Upgraded
Lantern Pharma Inc. (LTRN) was upgraded to D- from E+ on 6/28/2023 due to an increase in the volatility index and total return index.
Lantern Pharma Inc. (LTRN) was upgraded to D- from E+ on 6/28/2023 due to an increase in the volatility index and total return index.
E
Sell
6/12/2023Downgrade
Lantern Pharma Inc. (LTRN) was downgraded to E+ from D- on 6/12/2023 due to a decline in the volatility index.
Lantern Pharma Inc. (LTRN) was downgraded to E+ from D- on 6/12/2023 due to a decline in the volatility index.
D
Sell
5/22/2023Upgraded
Lantern Pharma Inc. (LTRN) was upgraded to D- from E+ on 5/22/2023 due to an increase in the volatility index, solvency index and growth index.
Lantern Pharma Inc. (LTRN) was upgraded to D- from E+ on 5/22/2023 due to an increase in the volatility index, solvency index and growth index.
E
Sell
5/12/2023Downgrade
Lantern Pharma Inc. (LTRN) was downgraded to E+ from D- on 5/12/2023 due to a decline in the volatility index, growth index and total return index.
Lantern Pharma Inc. (LTRN) was downgraded to E+ from D- on 5/12/2023 due to a decline in the volatility index, growth index and total return index.
D
Sell
4/24/2023Upgraded
Lantern Pharma Inc. (LTRN) was upgraded to D- from E+ on 4/24/2023 due to an increase in the volatility index.
Lantern Pharma Inc. (LTRN) was upgraded to D- from E+ on 4/24/2023 due to an increase in the volatility index.
E
Sell
4/6/2023Downgrade
Lantern Pharma Inc. (LTRN) was downgraded to E+ from D- on 4/6/2023 due to a decline in the volatility index and total return index.
Lantern Pharma Inc. (LTRN) was downgraded to E+ from D- on 4/6/2023 due to a decline in the volatility index and total return index.
D
Sell
3/21/2023Upgraded
Lantern Pharma Inc. (LTRN) was upgraded to D- from E+ on 3/21/2023 due to an increase in the volatility index and valuation index.
Lantern Pharma Inc. (LTRN) was upgraded to D- from E+ on 3/21/2023 due to an increase in the volatility index and valuation index.
E
Sell
3/16/2023Downgrade
Lantern Pharma Inc. (LTRN) was downgraded to E+ from D- on 3/16/2023 due to a decline in the total return index and volatility index.
Lantern Pharma Inc. (LTRN) was downgraded to E+ from D- on 3/16/2023 due to a decline in the total return index and volatility index.
D
Sell
2/27/2023Downgrade
Lantern Pharma Inc. (LTRN) was downgraded to D- from D on 2/27/2023 due to a decline in the volatility index.
Lantern Pharma Inc. (LTRN) was downgraded to D- from D on 2/27/2023 due to a decline in the volatility index.
D
Sell
2/9/2023Upgraded
Lantern Pharma Inc. (LTRN) was upgraded to D from E+ on 2/9/2023 due to an increase in the volatility index and total return index.
Lantern Pharma Inc. (LTRN) was upgraded to D from E+ on 2/9/2023 due to an increase in the volatility index and total return index.
E
Sell
2/8/2023Downgrade
Lantern Pharma Inc. (LTRN) was downgraded to E+ from D on 2/8/2023 due to a decline in the volatility index.
Lantern Pharma Inc. (LTRN) was downgraded to E+ from D on 2/8/2023 due to a decline in the volatility index.
D
Sell
2/6/2023Upgraded
Lantern Pharma Inc. (LTRN) was upgraded to D from D- on 2/6/2023 due to a noticeable increase in the growth index, total return index and volatility index. EBIT increased 51.19% from -$4.39M to -$2.15M, and earnings per share increased from -$0.4148 to -$0.2089.
Lantern Pharma Inc. (LTRN) was upgraded to D from D- on 2/6/2023 due to a noticeable increase in the growth index, total return index and volatility index. EBIT increased 51.19% from -$4.39M to -$2.15M, and earnings per share increased from -$0.4148 to -$0.2089.
D
Sell
9/6/2022Upgraded
Lantern Pharma Inc. (LTRN) was upgraded to D- from E+ on 9/6/2022 due to an increase in the total return index, volatility index and valuation index.
Lantern Pharma Inc. (LTRN) was upgraded to D- from E+ on 9/6/2022 due to an increase in the total return index, volatility index and valuation index.
E
Sell
8/18/2022Downgrade
Lantern Pharma Inc. (LTRN) was downgraded to E+ from D- on 8/18/2022 due to a decline in the growth index, total return index and volatility index. Earnings per share declined from -$0.379 to -$0.4148, and EBIT declined 8.08% from -$4.07M to -$4.39M.
Lantern Pharma Inc. (LTRN) was downgraded to E+ from D- on 8/18/2022 due to a decline in the growth index, total return index and volatility index. Earnings per share declined from -$0.379 to -$0.4148, and EBIT declined 8.08% from -$4.07M to -$4.39M.
D
Sell
5/4/2022Upgraded
Lantern Pharma Inc. (LTRN) was upgraded to D- from E+ on 5/4/2022 due to an increase in the total return index and valuation index.
Lantern Pharma Inc. (LTRN) was upgraded to D- from E+ on 5/4/2022 due to an increase in the total return index and valuation index.
E
Sell
4/20/2022Downgrade
Lantern Pharma Inc. (LTRN) was downgraded to E+ from D- on 4/20/2022 due to a decline in the total return index and solvency index. The quick ratio declined from 41.39 to 30.48.
Lantern Pharma Inc. (LTRN) was downgraded to E+ from D- on 4/20/2022 due to a decline in the total return index and solvency index. The quick ratio declined from 41.39 to 30.48.
D
Sell
11/3/2021Downgrade
Lantern Pharma Inc. (LTRN) was downgraded to D- from D on 11/3/2021 due to a large decline in the volatility index, growth index and total return index. Operating cash flow declined 171.38% from -$1.73M to -$4.68M, earnings per share declined from -$0.2072 to -$0.3624, and EBIT declined 67.36% from -$2.48M to -$4.15M.
Lantern Pharma Inc. (LTRN) was downgraded to D- from D on 11/3/2021 due to a large decline in the volatility index, growth index and total return index. Operating cash flow declined 171.38% from -$1.73M to -$4.68M, earnings per share declined from -$0.2072 to -$0.3624, and EBIT declined 67.36% from -$2.48M to -$4.15M.
D
Sell
7/1/2021Upgraded
Lantern Pharma Inc. (LTRN) was upgraded to D from D- on 7/1/2021 due to an increase in the valuation index, solvency index and volatility index. The quick ratio increased from 34.81 to 122.45, and debt to equity declined from 0.01 to 0.
Lantern Pharma Inc. (LTRN) was upgraded to D from D- on 7/1/2021 due to an increase in the valuation index, solvency index and volatility index. The quick ratio increased from 34.81 to 122.45, and debt to equity declined from 0.01 to 0.
D
Sell
3/1/2021Upgraded
Lantern Pharma Inc. (LTRN) was upgraded to D- from E on 3/1/2021 due to an increase in the total return index.
Lantern Pharma Inc. (LTRN) was upgraded to D- from E on 3/1/2021 due to an increase in the total return index.
E
Sell
12/23/2020Downgrade
Lantern Pharma Inc. (LTRN) was downgraded to E from E+ on 12/23/2020 due to a decline in the valuation index.
Lantern Pharma Inc. (LTRN) was downgraded to E from E+ on 12/23/2020 due to a decline in the valuation index.
E
Sell
12/8/2020Upgraded
Lantern Pharma Inc. (LTRN) was upgraded to E+ from E on 12/8/2020 due to an increase in the valuation index.
Lantern Pharma Inc. (LTRN) was upgraded to E+ from E on 12/8/2020 due to an increase in the valuation index.
E
Sell
12/1/2020Upgraded
Lantern Pharma Inc. (LTRN) was upgraded to E from E- on 12/01/2020.
Lantern Pharma Inc. (LTRN) was upgraded to E from E- on 12/01/2020.
E
Sell
11/12/2020Downgrade
Lantern Pharma Inc. (LTRN) was downgraded to E- from E on 11/12/2020 due to a decline in the efficiency index, valuation index and solvency index. Net income declined 104.16% from -$833.4 to -$1.7M, and total capital declined 7.51% from $23.44M to $21.68M.
Lantern Pharma Inc. (LTRN) was downgraded to E- from E on 11/12/2020 due to a decline in the efficiency index, valuation index and solvency index. Net income declined 104.16% from -$833.4 to -$1.7M, and total capital declined 7.51% from $23.44M to $21.68M.
E
Sell
11/3/2020Upgraded
Lantern Pharma Inc. (LTRN) was upgraded to E from E- on 11/3/2020 due to an increase in the total return index and valuation index.
Lantern Pharma Inc. (LTRN) was upgraded to E from E- on 11/3/2020 due to an increase in the total return index and valuation index.
E
Sell
9/18/2020Downgrade
Lantern Pharma Inc. (LTRN) was downgraded to E- from E on 9/18/2020 due to a decline in the valuation index.
Lantern Pharma Inc. (LTRN) was downgraded to E- from E on 9/18/2020 due to a decline in the valuation index.
E
Sell
9/3/2020None
Lantern Pharma Inc. (LTRN) was downgraded to E from U on 09/03/2020.
Lantern Pharma Inc. (LTRN) was downgraded to E from U on 09/03/2020.
NASDAQ
03/17/2025 3:59PM Eastern
Quotes delayed
